BEIJING (Reuters) - China's Ministry of Commerce has approved Baxter International Inc's $4 billion bid for Sweden's Gambro AB provided Baxter sells its global continuous renal replacement therapy ...
Includes intended Phase I clinical trial designed to generate key evidence to support additional therapeutic options for patients suffering from acute liver failure “Miromatrix believes that ...
Baxter International Inc. BAX recently received the FDA’s 510(k) clearance for its ST Set used in continuous renal replacement therapy (“CRRT”). The system is expected to offer additional options to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback